$SMTI
Sanara MedTech Inc. Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223008240 Filed on March 20, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$15.52M	$15.32M	$45.84M
YoY Change	98.71%	117.76%	89.87%
Cost Of Revenue	$2.126M	$2.369M	$6.361M
YoY Change	164.03%	202.66%	175.22%
Gross Profit	$13.40M	$12.95M	$39.48M
YoY Change	91.21%	107.13%	80.84%
Gross Profit Margin	86.31%	84.53%	86.12%
Selling, General & Admin	$12.97M	$14.11M	$45.98M
YoY Change	38.33%	54.02%	63.89%
% of Gross Profit	96.81%	108.98%	116.45%
Research & Development	$1.317M	$1.034M	$3.367M
YoY Change	543.73%	243.71%	502.65%
% of Gross Profit	9.83%	7.99%	8.53%
Depreciation & Amortization	$107.7K	$814.3K	$407.8K
YoY Change	-46.89%	305.11%	-31.69%
% of Gross Profit	0.8%	6.29%	1.03%
Operating Expenses	$14.61M	$15.96M	$51.71M
YoY Change	49.37%	65.15%	77.05%
Operating Profit	-$1.216M	-$3.012M	-$12.23M
YoY Change	-56.2%	-11.75%	65.84%
Interest Expense	$6.00	$0.00	$284.7K
YoY Change		-100.0%	-146.1%
% of Operating Profit
Other Income/Expense, Net	-$6.00	-$111.6K	-$1.705M
YoY Change	-100.0%
Pretax Income	-$1.216M	-$4.163M	-$13.94M
YoY Change	-61.47%	17.06%	74.35%
Income Tax		$0.00	-$5.845M
% Of Pretax Income
Net Earnings	-$1.178M	-$4.107M	-$7.937M
YoY Change	-62.68%	15.75%	0.2%
Net Earnings / Revenue	-7.59%	-26.82%	-17.31%
Basic Earnings Per Share	-$0.14		-$1.00
Diluted Earnings Per Share	-$0.14	-$0.51	-$1.00
COMMON SHARES
Basic Shares Outstanding	8.377M shares	8.304M shares	7.907M shares
Diluted Shares Outstanding	8.174M shares		7.907M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.286M	$8.959M	$8.959M
YoY Change	-54.86%	-51.97%	-51.97%
Cash & Equivalents	$7.286M	$8.959M
Short-Term Investments
Other Short-Term Assets	$1.748M	$1.105M	$1.105M
YoY Change	179.77%	20.42%	20.42%
Inventory	$3.432M	$3.549M	$3.549M
Prepaid Expenses
Receivables	$6.541M	$6.806M	$7.004M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$19.01M	$20.62M	$20.62M
YoY Change	-15.5%	-16.22%	-16.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.336M	$1.416M	$2.223M
YoY Change	-30.93%	-13.09%	8.82%
Goodwill	$3.602M	$3.602M
YoY Change
Intangibles	$30.84M	$31.51M
YoY Change		566.46%
Long-Term Investments	$3.084M	$3.084M	$3.084M
YoY Change	-36.9%	-38.53%	-38.53%
Other Assets
YoY Change
Total Long-Term Assets	$40.96M	$40.42M	$40.42M
YoY Change	258.05%	242.88%	242.88%
TOTAL ASSETS
Total Short-Term Assets	$19.01M	$20.62M	$20.62M
Total Long-Term Assets	$40.96M	$40.42M	$40.42M
Total Assets	$59.97M	$61.04M	$61.04M
YoY Change	76.72%	67.7%	67.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.821M	$1.393M	$1.427M
YoY Change	85.62%	217.86%	140.2%
Accrued Expenses	$8.094M	$10.22M	$10.22M
YoY Change	90.46%	88.21%	88.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.60M	$12.81M	$12.81M
YoY Change	102.67%	112.65%	112.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.028M	$6.004M	$6.509M
YoY Change	3122.63%		2830.05%
Total Long-Term Liabilities	$7.887M	$6.509M	$6.509M
YoY Change	4116.63%	2830.03%	2830.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.60M	$12.81M	$12.81M
Total Long-Term Liabilities	$7.887M	$6.509M	$6.509M
Total Liabilities	$18.49M	$19.32M	$19.21M
YoY Change	277.13%	209.32%	233.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.91M	-$23.39M
YoY Change		53.56%
Common Stock	$66.54M	$65.22M
YoY Change		42.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.62M	$41.83M	$41.83M
YoY Change
Total Liabilities & Shareholders Equity	$59.97M	$61.04M	$61.04M
YoY Change	76.72%	67.7%	67.7%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$1.178M	-$4.107M	-$7.937M
YoY Change	-62.68%	15.75%	0.2%
Depreciation, Depletion And Amortization	$107.7K	$814.3K	$407.8K
YoY Change	-46.89%	305.11%	-31.69%
Cash From Operating Activities	-$1.741M	-$645.0K	-$5.555M
YoY Change	-17.57%	-63.85%	15.38%
INVESTING ACTIVITIES
Capital Expenditures	$27.71K	$53.37K	$147.0K
YoY Change	-161.98%	-137.66%	-119.59%
Acquisitions
YoY Change
Other Investing Activities	$650.00	-$323.6K	-$2.765M
YoY Change	-100.26%	-76.03%	-39.03%
Cash From Investing Activities	-$27.06K	-$376.9K	-$3.512M
YoY Change	-90.81%	-74.73%	-33.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$95.81K	-304.4K	-$627.3K
YoY Change	-193.08%	-31.21%	-102.22%
NET CHANGE
Cash From Operating Activities	-$1.741M	-645.0K	-$5.555M
Cash From Investing Activities	-$27.06K	-376.9K	-$3.512M
Cash From Financing Activities	$95.81K	-304.4K	-$627.3K
Net Change In Cash	-$1.673M	-1.326M	-$9.694M
YoY Change	-33.36%	-64.33%	-153.27%
FREE CASH FLOW
Cash From Operating Activities	-$1.741M	-$645.0K	-$5.555M
Capital Expenditures	$27.71K	$53.37K	$147.0K
Free Cash Flow	-$1.769M	-$698.4K	-$5.702M
YoY Change	-14.45%	-57.48%	40.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000714256
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Accretion Expense AccretionExpense		usd
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1		usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022	SMTI	License Agreement As Capital Contribution From Noncontrolling Interest LicenseAgreementAsCapitalContributionFromNoncontrollingInterest		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber		shares
CY2021Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2022	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost		usd
CY2021Q4	SMTI	Deferred Tax Liabilities Accrued Expenses DeferredTaxLiabilitiesAccruedExpenses		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39678
CY2022	dei	Entity Registrant Name EntityRegistrantName	SANARA MEDTECH INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2219994
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Summit Ave
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 414
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76102
CY2022	dei	City Area Code CityAreaCode	(817)
CY2022	dei	Local Phone Number LocalPhoneNumber	529-2300
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022	dei	Trading Symbol TradingSymbol	SMTI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	69503434	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8376833	shares
CY2022	dei	Auditor Firm AuditorFirmId	410
CY2022	dei	Auditor Name AuditorName	Weaver and Tidwell, L.L.P
CY2022	dei	Auditor Location AuditorLocation	Austin, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8958995	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18652841	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6805761	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2861014	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	98548	usd
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	79787	usd
CY2022Q4	SMTI	Royalty Receivable RoyaltyReceivable	99594	usd
CY2021Q4	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3549000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2048191	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1104611	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	917318	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	20616509	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	24608495	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1629845	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	806402	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	412770	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	31509980	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4727970	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	5017351	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	40418877	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	11787936	usd
CY2022Q4	us-gaap	Assets Assets	61035386	usd
CY2021Q4	us-gaap	Assets Assets	36396431	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1392701	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	438154	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	34036	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	155817	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2144475	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	706196	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7758284	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	4518817	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1162880	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	313933	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	203292	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12806309	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6022276	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6003811	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	505291	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	222151	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6509102	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	222151	usd
CY2022Q4	us-gaap	Liabilities Liabilities	19315411	usd
CY2021Q4	us-gaap	Liabilities Liabilities	6244427	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8299957	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8299957	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7676662	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7676662	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8300	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7677	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65213987	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	45867768	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23394757	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15235044	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	41827530	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	30640401	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-107555	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-488397	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61035386	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36396431	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45842845	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24143919	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	6360851	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	2311221	usd
CY2022	us-gaap	Gross Profit GrossProfit	39481994	usd
CY2021	us-gaap	Gross Profit GrossProfit	21832698	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45976328	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28053176	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3367032	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	558704	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2371068	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	596975	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	51714428	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	29208855	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-12232434	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-7376157	usd
CY2022	us-gaap	Interest Expense InterestExpense	284746	usd
CY2021	us-gaap	Interest Expense InterestExpense	711	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-616927	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-1040311	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1704690	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-617638	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13937124	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7993795	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5844796	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8092328	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-7993795	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-154831	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-71881	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7937497	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7921914	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7906794	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7341580	shares
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5840236	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1580708	usd
CY2021	SMTI	Net Settlement And Retirement Of Equity Based Awards NetSettlementAndRetirementOfEquityBasedAwards	-442525	usd
CY2021	SMTI	Stock Issued During Period Value Common Stock For Acquisitions StockIssuedDuringPeriodValueCommonStockForAcquisitions	2334244	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	28939257	usd
CY2021	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	200000	usd
CY2021	SMTI	Capital Contribution Of Noncontrolling Interest CapitalContributionOfNoncontrollingInterest	93879	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-7993795	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30152004	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3790817	usd
CY2022	SMTI	Net Settlement And Retirement Of Equity Based Awards NetSettlementAndRetirementOfEquityBasedAwards	-407346	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	11125872	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4612645	usd
CY2022	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	220000	usd
CY2022	SMTI	Dissolution Of Investment DissolutionOfInvestment	758311	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8092328	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8092328	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-7993795	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2371068	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	596975	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2634	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-41	usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	28939257	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-407346	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	280000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	51536	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	540090	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	251826	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2702633	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2668892	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	284540	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	263518	usd
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	174955	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-616927	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-1040311	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5844796	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2250223	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	695018	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	18761	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	79787	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	517271	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1151764	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	159592	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	305501	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-301966	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	166903	usd
CY2022	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-121781	usd
CY2021	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	-67772	usd
CY2022	SMTI	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	1156279	usd
CY2021	SMTI	Increase Decrease In Royalty Payable IncreaseDecreaseInRoyaltyPayable	204005	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2994512	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	923063	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-263370	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-176012	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5554870	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4814526	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	147015	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	171867	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1549	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	600000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	578586	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	250000	usd
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	4534278	usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2516164	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3511630	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5284731	usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	800000	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	800000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-442525	usd
CY2022	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	220000	usd
CY2021	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	200000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-627346	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28296732	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9693846	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	18197475	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18652841	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	455366	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18652841	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	206	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	711	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	15738517	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	2334244	usd
CY2022	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	6882151	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1803440	usd
CY2021	SMTI	License Agreement As Capital Contribution From Noncontrolling Interest LicenseAgreementAsCapitalContributionFromNoncontrollingInterest	93879	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zCgMpwrAtna2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_824_zstXX7QaTsmc">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (together with its wholly owned and majority owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies contributes to the Company’s overall goal of achieving better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zpm7WkEm4R9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zuc9LAqyktKk">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	523832	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	333850	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	251826	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45842845	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24143919	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	280000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	51536	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	265089	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	64899	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4761	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	34379	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	540090	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2156422	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1972419	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	739986	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	342574	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1416436	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1629845	usd
CY2022	us-gaap	Depreciation Depreciation	407769	usd
CY2021	us-gaap	Depreciation Depreciation	220571	usd
CY2021Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	584244	usd
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	1162830	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	6000000.0	usd
CY2022	SMTI	Business Combination Consideration Transferred Net Income Loss BusinessCombinationConsiderationTransferredNetIncomeLoss	1000000.0	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	51770977	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	30783017	usd
CY2022	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-7356563	usd
CY2021	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-8344339	usd
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y3M18D
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1963299	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	376404	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2780806	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2780806	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2780806	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2763550	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2649698	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	17754314	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	31509980	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2021Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	2834278	usd
CY2022Q4	us-gaap	Investments Investments	3084278	usd
CY2021Q4	us-gaap	Investments Investments	5017351	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-616927	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-379633	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-616927	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	806402	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	819224	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	297136	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	202498	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	296988	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	203555	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	354165	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	283581	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	168269	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	79161	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6727	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	891903	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	72679	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	819224	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	313933	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	505291	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0621	pure
CY2022	us-gaap	Royalty Expense RoyaltyExpense	1771219	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	856755	usd
CY2020Q2	us-gaap	Cash Cash	500000	usd
CY2022	us-gaap	Payments For Royalties PaymentsForRoyalties	201000	usd
CY2022Q4	us-gaap	Payments For Royalties PaymentsForRoyalties	50250	usd
CY2022	SMTI	Annual Royalty Obligation AnnualRoyaltyObligation	16080	usd
CY2022Q4	SMTI	Annual Royalty Obligation AnnualRoyaltyObligation	4020	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	SMTI	Transaction Expenses TransactionExpenses	600000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	us-gaap	Share Price SharePrice	30.75
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	SMTI	Transaction Expenses TransactionExpenses	600000	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	165738	shares
CY2022Q2	us-gaap	Share Price SharePrice	30.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	27.13
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	173959	shares
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	4361698	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2702633	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2668892	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1038183	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2275010	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y8M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	161450	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	18.13
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	184640	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.98
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	154307	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	20.37
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	10681	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	23.44
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	181102	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	22.89
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.00
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.71
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.00
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	146191	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.65
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	146191	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.65
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	16725	shares
CY2022	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice	10.80
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2022Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2022	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2022Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	16725	shares
CY2022Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
CY2022	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5800000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	32500000	usd
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5400000	usd
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	expire between 2023 and 2037.
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Amount EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount	27100000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6818547	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4352201	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	43678	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	70221	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	92286	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	561944	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	35579	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	707076	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	232250	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26102	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1134	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7919939	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5021079	usd
CY2022Q4	SMTI	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	5919626	usd
CY2021Q4	SMTI	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	17001	usd
CY2022Q4	SMTI	Deferred Tax Liabilities Accrued Expenses DeferredTaxLiabilitiesAccruedExpenses	26903	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1973410	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5004078	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2851758	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1663601	usd
CY2022	SMTI	Income Tax Reconciliation Income Tax Expense Nol Carryover Adjusted For Expiration IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration	-46936	usd
CY2021	SMTI	Income Tax Reconciliation Income Tax Expense Nol Carryover Adjusted For Expiration IncomeTaxReconciliationIncomeTaxExpenseNOLCarryoverAdjustedForExpiration	29730	usd
CY2022	SMTI	Income Tax Reconciliation Expense Equity Method Investment Loss IncomeTaxReconciliationExpenseEquityMethodInvestmentLoss	79723	usd
CY2021	SMTI	Income Tax Reconciliation Expense Equity Method Investment Loss IncomeTaxReconciliationExpenseEquityMethodInvestmentLoss	129555	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	4843	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	7439	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	249516	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-120924	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	707076	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-329829	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	46683	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-3657431	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1571118	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5844796	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
smti-20221231_cal.xml	Edgar Link	unprocessable
0001493152-23-008240-index-headers.html	Edgar Link	pending
0001493152-23-008240-index.html	Edgar Link	pending
0001493152-23-008240.txt	Edgar Link	pending
0001493152-23-008240-xbrl.zip	Edgar Link	pending
ex10-15.htm	Edgar Link	pending
ex10-1_1.htm	Edgar Link	pending
ex10-1_3.htm	Edgar Link	pending
ex10-1_4.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20221231.xsd	Edgar Link	pending
smti-20221231_def.xml	Edgar Link	unprocessable
smti-20221231_lab.xml	Edgar Link	unprocessable
smti-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara MedTech Inc. Stock $smti

2023 Q1 Form 10-K Financial Statement

#000149315223008240 Filed on March 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara MedTech Inc. Stock $smti

2023 Q1 Form 10-K Financial Statement

#000149315223008240 Filed on March 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara MedTech Inc. Stock $smti